Jiangsu Nhwa Pharmaceutical (002262) Q3 2026 earnings summary

Executive summary

• Q3 revenue rose 6.61% YoY to RMB1.557bn; attributable net income was nearly flat at RMB405.5m, while adjusted net income increased 1.06% to RMB413.5m.

• YTD revenue grew 6.81% to RMB4.776bn and attributable net income rose 3.63% to RMB1.146bn.

Financial highlights

• Q3 basic and diluted EPS were RMB0.40, flat YoY; YTD EPS was RMB1.14, up 4.59%.

• YTD adjusted net income, excluding non-recurring items, was RMB1.159bn, up 4.59%; non-recurring losses totaled RMB13.32m.

• Total assets were RMB9.906bn, up 7.41% from year-end; attributable equity was RMB8.799bn, up 9.21%.

Key financial ratios and metrics

• YTD weighted-average ROE was 13.56%, down 0.75 percentage points YoY; Q3 ROE was 4.72%, down 0.42 points.

• YTD operating cash flow was RMB858.6m, down 5.76% YoY.